User:NickCT/LixiLan
LixiLan is the trade name of a drug being developed by Sanofi for treatment of diabetes. The drug is a combination therapy and combines the two diabetes drugs insulin glargine and lixisenatide.[1] In 2016 Sanofi announced the drug had produced positive results in Phase III clinical trails and suggested that the drug would be approved by the Food and Drug Administration in 2017.[2]
References
[edit]- ^ "SANOFI ANNOUNCES POSITIVE PHASE 3 RESULTS FOR INVESTIGATIONAL TITRATABLE FIXED-RATIO COMBINATION OF INSULIN GLARGINE AND LIXISENATIDE" (Press release). Sanofi. 12 June 2016. Retrieved 2016-09-19.
- ^ Blamont, Matthias (12 June 2016). "Sanofi says LixiLan diabetes drug trials meet targets". Reuters. Retrieved 19 September 2016.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |